Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | FPR1 | P21462 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528335 | 0.91 | SLC6A3 (0.43) | SLC6A4SLC6A3SLC6A2JAK2JAK1 | |
| SCHEMBL3530380 | 0.84 | JAK2 (0.47) | JAK2JAK1TACR1 | |
| SCHEMBL6153201 | 0.82 | METAP2 (0.38) | MCHR1 | |
| SCHEMBL6154363 | 0.82 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2HTR1AMAPT | |
| SCHEMBL27640160 | 0.79 | SLC6A4 (0.38) | SLC6A4SLC6A3SLC6A2FPR1FPR2 | |
| SCHEMBL5380104 | 0.78 | CCR1 (0.50) | MAPT | |
| SCHEMBL3529341 | 0.76 | SLC6A3 (0.43) | SLC6A4SLC6A3JAK2JAK1 | |
| SCHEMBL3530635 | 0.76 | KDM1A (0.39) | MAPTJAK2JAK1 | |
| SCHEMBL3528223 | 0.75 | JAK2 (0.46) | JAK2JAK1TACR1 | |
| SCHEMBL30479381 | 0.75 | JAK2 (0.46) | JAK2JAK1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | SLC6A4 1478/4885SLC6A3 1496/4885SLC6A2 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.